Leerink downgraded American Renal Associates (NYSE:ARA) to “market perform” but raised its price target to $27 from $17, citing a fuller valuation after the company reported fourth quarter results. The stock closed at $23.52 on March 7.Read More
Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday.
“Our positive thesis contemplates a forward adjusted EBITDA (excluding non-controlling interest) growth rate of 13% (2015-2019 estimated CAGR) and is based on three growth pillars,” writes analyst Ana Gupte.Read More